Company Active LTD

Company profile

Bioxydyn Limited

UK company 06838431, incorporated on 5 March 2009.

Bioxydyn - Imaging Biomarker Services

Bioxydyn Limited is a UK company with status active founded in 2009.

Company number
06838431
Incorporated
5 Mar 2009
Companies House status
Active

Company identity

Founded / incorporated
5 March 2009

Company number 06838431

Verify at Companies House
Legal name
BIOXYDYN LIMITED
Company type
LTD
Region
Unknown
Registered address
Unknown
Insolvency history
No

Latest accounts

Financial period: 1 Dec 2023 to 30 Nov 2024

FILLETEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
7

Company events

Reference milestones and recent Companies House filing stream events.

2 events
31 Aug
2026

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzU0MTcxMDU2MmFkaXF6a2N4

Published 31 Aug 2026 11:54

05 Mar
2009

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2013
Funded years
2013, 2019
Age at first award
4 years

Projects

2019 Collaborative R&D Lead participant

Oxygen enhanced lung MRI - towards clinical application

1 Mar 2019 to 31 Mar 2021

Awarded
£68,151
Total cost £97,359

"The lung is poorly served by non-ionising or low-dose imaging technologies. Thoracic CT scanning is the main technique available, but does not permit routine follow-up or longitudinal monitoring because of the unacceptably high radiation dose, especially in children. Bioxydyn Ltd is an imaging services business offering quantitative MRI biomarkers for ph...

2013 GRD Development of Prototype Lead participant

3D functional oxygen-enhanced lung imaging

1 Jun 2013 to 31 Dec 2014

Awarded
£249,989
Total cost £739,395

Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease, characterized by airflow obstruction to the lungs, interfering with normal breathing. It is one of the most common respiratory diseases and the WHO predicts it to be the 3rd leading cause of death worldwide by 2020. Early clinical diagnosis is critical to prevent further deteri...

Product types

Collaborative R&D GRD Development of Prototype